Table.
Characteristics of infants with neonatal abstinence syndrome (NAS) reported to the Tennessee NAS public health surveillance system (TNSS), 2013-2016
| Characteristic |
Cumulative
No. (%) (n = 4070) |
|---|---|
| NAS severitya | |
| Severe | 691 (65) |
| Mild | 365 (34) |
| Elements used to support making an NAS diagnosisb | |
| Maternal history of using a substance known to cause NAS | 3756 (92) |
| Maternal screening test for a substance known to cause NAS | 2376 (58) |
| Neonatal screening test for a substance known to cause NAS | 2204 (54) |
| Maternal sources of exposureb | |
| Medication-assisted treatment (eg, methadone or buprenorphine) | 2389 (59) |
| Legally prescribed opioid pain reliever (eg, hydrocodone or oxycodone) | 521 (13) |
| Prescription opioid without a prescriptiona (eg, taking someone else’s opioid pain medication) | 289 (27) |
| Legally prescribed nonopioid (eg, benzodiazapene) | 321 (8) |
| Prescription nonopioid without a prescriptiona (eg, taking someone else’s benzodiazepine) | 120 (11) |
| Nonprescription substance excluding heroin (eg, cocaine or methamphetamine) | 881 (22) |
| Heroina | 40 (4) |
| Other | 30 (1) |
a Reports 2016 data only, when TNSS surveillance added these variables. The denominator for percentages in these rows is 1063.
b Categories are not mutually exclusive.